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Background: Frontotemporal dementia (FTD) is recognised as a clinically and morphologically heterogeneous
group of interrelated neurodegenerative conditions. One of the subtypes within this disease spectrum is the
behavioural variant FTD (bvFTD). This is known to be a varied disorder with a mixture of tau-positive and tau-
negative underlying pathologies. The other subtypes include semantic dementia (SD), which generally exhibits tau-
negative pathology, and progressive non-fluent aphasia (PNFA), which is usually tau-positive. As the clinical
presentation of these subtypes may overlap, a specific diagnosis can be difficult to attain and today no specific
biomarker can predict the underlying pathology. Neurofilament light chain protein (NFL), a cytoskeletal constituent
of intermediate filaments, is thought to reflect neuronal and axonal death when appearing in the cerebrospinal
fluid (CSF). NFL has been shown to be elevated in CSF in patients with FTD compared with AD and controls. Our
hypothesis was that the levels of NFL also differ between the subtypes of FTD and may indicate the underlying
pathological subtype.
Methods: We retrospectively analysed data from previous CSF analyses in 34 FTD cases (23 bvFTD, seven SD, four
PNFA), 20 AD cases, and 26 healthy controls. A separate group of 10 neuropathologically verified and subtyped FTD
cases (seven tau-negative, three tau-positive) were also analysed.
Result: NFL levels were significantly higher in FTD compared with both AD (p<0.001) and controls (p<0.001). The
NFL levels of SD and bvFTD were significantly higher (p<0.001) compared with AD. The biomarker profiles of PNFA
and AD were similar. In the neuropathologically verified FTD cases, NFL was higher in the tau-negative than in the
tau-positive cases (exact p=0.017).
Conclusions: The marked NFL elevation in some but not all FTD cases is likely to reflect the different underlying
pathologies. The highest NFL values found in the SD group as well as in the neuropathologically verified tau-
negative cases may be of subtype diagnostic value, if corroborated in larger patient cohorts. In bvFTD, a mixture of
tau-positive and tau-negative underlying pathologies could possibly explain the intermediate NFL values.
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Frontotemporal dementia (FTD) is a heterogeneous group
of neurodegenerative conditions affecting the frontal and
temporal lobes and, to a varying degree, the subcortical
grey matter. In the 1998 consensus document, FTD was
divided into a number of clinical subtypes: behavioural
variant (bvFTD) and progressive aphasias, semantic de-
mentia (SD) and progressive non-fluent aphasia (PNFA)
[1]. There is a close association, both clinically and
neuropathologically, with corticobasal degeneration (CBD)
and progressive supranuclear palsy (PSP); thus these diag-
noses are now generally considered part of the FTD
spectrum [2].
There is considerable overlap between the different
subtypes of FTD, both clinically and neuropathologically.
A major challenge in diagnosing FTD is the difficulty in
predicting a neuropathological subtype based on clinical
characteristics. With reference to protein pathology, cases
of FTD have previously been recognised as tau-positive or
tau-negative. Among the tau-positive pathologies, cases of
Pick’s disease and FTD with tau-positive inclusions have
been found. The majority of tau-negative cases have been
ubiquitin-positive. In 2006, TDP-43 was identified in the
ubiquitin-positive inclusions in the majority of these cases
[3] and, recently, FUS-positive pathology was identified in
most of the remaining cases [4,5]. The remaining small
group exhibits a spectrum of variable morphological fac-
tors [6,7]. There is not always a clear congruence between
the clinical and neuropathological subtypes of FTD. While
bvFTD can reflect any of the neuropathological subtypes,
SD almost exclusively shows TDP-43 pathology and PNFA
most often shows tau-positive inclusions [8]. FTD with
concomitant motor neuron disease (FTD-MND) most
often exhibits TDP-43 pathology.
In AD, the analysis of cerebrospinal fluid (CSF) bio-
markers (with a typical pattern of elevated tau, phosphory-
lated tau [phospho-tau] and decreased beta-amyloid 42
[Aβ42]) is an acknowledged and promising tool in the
diagnosis of Alzheimer’s disease [9]. However, there are no
reliable CSF biomarkers available for FTD in general or
for the different FTD subtypes. A previous study demon-
strated that CSF levels of TDP-43 were slightly increased
in amyotrophic lateral sclerosis (ALS) compared with
controls [10], but its role in the clinical diagnosis of FTD
is yet to be determined.
Neurofilament proteins, when prevalent in the CSF,
are considered to reflect neuronal degeneration. These
intermediate filaments form a major cytoskeletal con-
stituent of neurons and they comprise the neurofilament
heavy (NFH), intermediate (NFM) and light (NFL) chain
proteins, the latter being a non-phosphorylated form.
NFL levels are slightly augmented in healthy aging
individuals and have been correlated with increasing age
[11]. In acute cerebral infarction, very high NFL levelscan be seen. The levels are higher in VaD than in AD
[12]. A recent study [13] showed that NFL levels were
significantly higher in atypical parkinsonian disorders
(CBD and multiple system atrophy) compared with
Parkinson’s disease; whereas NFL levels in Lewy body
dementia were intermediate. The suggested explanation
for these differences was that patients with atypical
parkinsonian disorders experienced a greater loss of
neurons over a shorter period of time. NFL levels are
also increased in individuals with white matter disease
(WMD) [14]. WMD is common in patients with demen-
tia (AD, among other diseases), but can also be seen in
healthy older adults [15]. WMD is indicated by
hyperintensities visualised during life as punctuate or
confluent changes in the periventricular regions or deep
white matter on computerized tomography or magnetic
resonance imaging scans [15,16].
Some studies have shown that CSF levels of NFL are
higher in FTD compared with both early-onset AD and
controls [17,18]. In ALS it has also been shown that
NFL is often considerably increased compared with
controls [19,20], and elevated levels of NFL correlate
with shorter survival [19].
The aim of this study was to investigate whether existing
CSF biochemical markers, in particular NFL, can assist in
the differential diagnostics of frontotemporal dementias.
Can biomarkers help us differentiate between clinical
and/or neuropathological subtypes of frontotemporal
dementias? Furthermore, is the severity of the disease
post mortem related to in vivo NFL levels?
Methods
Patients/study population
This study focused on two populations: 1. a clinical cohort
of 34 FTD cases, 20 AD cases and 26 healthy controls and
2. a separate cohort of 10 post mortem verified FTD cases.
We re-evaluated the clinical files of all patients who
had been diagnosed with FTD, SD or progressive non-
fluent aphasia (PNFA) at the Memory Clinic, Lund
University Hospital and who had undergone a lumbar
puncture between 2002 and May 2010. A prerequisite
for inclusion was that patients’ neurofilament light chain
protein (NFL) levels had been previously analysed. The
method used to analyse NFL changed in June 2010;
hence only patients with CSF samples taken before this
time were included. Patients with a clinical diagnosis of
PSP or CBD were not included.
Clinical revision and subtyping
The clinical diagnoses of 44 eligible FTD patients were
revised and divided into subgroups according to the
1998 consensus criteria on FTD [1] by two independent
observers (one senior consultant [CN]) and one senior
neuropsychologist. Ten patients were excluded on the
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meet the clinical criteria or they presented other types of
brain lesions, i.e. strategic infarctions on neuroimaging,
or other lesions that could better explain their symp-
toms. In three cases, the conclusion of the two observers
differed and a consensus diagnosis was reached after
revision. The revised diagnoses were determined by
observers blinded to the CSF examination results. The
initial case selection, however, was established from the
existing medical records based on clinical diagnoses at the
time of investigation. Therefore at this initial stage the ob-
servers were not formally blinded to the CSF examination
results. These results, however, were not pivotal for the
diagnosis at this stage, but served to demonstrate that
none of the SD or bvFTD individuals had a CSF profile
typical of AD (high phospho-tau, low beta-amyloid).
Of the 34 patients included in the study, 23 patients
were diagnosed with bvFTD. Among these, two patients
did not fully meet all five core criteria of any of the
existing subgroups of FTD, but the suspicion of a disorder
within the FTD spectrum was strong and was further
supported by neuroimaging. The clinical characteristics in
these two cases were closest to the behavioural variant.
One of the two patients met the criteria of probable FTD
according to the recently suggested clinical criteria of
bvFTD [21]. Seven cases were diagnosed as SD and four
cases as PNFA based on existing clinical criteria [1].
A group of 20 age-matched AD patients were selected
as controls among the patients who had undergone a
diagnostic LP including NFL measurement between
2006–2008 and who met the NINCDS-ADRDA criteria
[22] for probable AD.
All patients, both within the FTD and AD groups, had
given their written consent to save CSF for research
purposes (biobank no. SC57; BD15; registry no. 136).
Additionally, the majority of the FTD patients were part
of ongoing longitudinal studies for which the Regional
Ethical Review Board at Lund University had given their
approval (dno. 617/2008, 16/2011, 137/2012). No new
CSF analyses were performed specifically for this study;
instead, the results from the clinical investigations were
used.
NFL data from a group of 26 age- and sex-matched
healthy controls were retrieved from research material
previously published by Zetterberg et al. 2007 [19].
A neuropathologically studied group of 10 FTD patients,
who during life had undergone a lumbar puncture with
measurement of NFL levels, was identified. The cases were
all morphologically diagnosed and typed at the Depart-
ment of Pathology at Lund University Hospital between
2001 and 2009.
Demographic data for both patients (age at onset, age
at LP, gender) and the control group (age at LP, gender)
was noted (Table 1).CSF analysis
CSF collection and analysis had been performed in a
clinical setting prior to this study, according to the
standardised procedure at the Memory Clinic in Lund.
In two cases, the lumbar puncture was carried out at
nearby Memory Clinics with similar routine procedures.
CSF was obtained by lumbar puncture and centrifuged
at 2000 g at +4°C for 10 min within 2 h of sampling. It
was then aliquoted, and stored in polypropylene tubes
at −80°C without being thawed and refrozen prior to
biochemical analysis. Basic CSF analyses of cells, pro-
tein, sp-Alb and the Alb ratio were performed at the
Department of Clinical Chemistry, Lund University
Hospital. The albumin ratio was calculated as CSF albu-
min (mg/L)/serum albumin (g/L) and was used as a
measure of blood–brain barrier function [23]. Analyses
of tau, p-tau, Aβ42 and NFL were performed at the
Clinical Neurochemistry Laboratory at the Sahlgrenska
University Hospital in Mölndal, Sweden, according to
previously described ELISA procedures [11,24-26]. The
detection limit of the NFL assay was 250 ng/L.Neuropathology
Prior to this study, all 10 cases were examined and diag-
nosed by the same neuropathologist (EE) according to the
diagnostic procedures at the Department of Pathology,
Lund. These procedures included whole brain assessment
with entire bi-hemispheric coronal sections covering all
major regions for conventional staining, including silver
stains and additional small area sections for immuno-
histochemical assessments of protein pathology. The
neuropathology procedure in Lund has been described
previously in detail [27]. For the present study, the 10
cases were revised for confirmation. The overall severity
of degeneration was noted as mild, moderate or severe,
judged from macroscopically assessed regional atrophy
and from microscopically assessed grading of cortical
degeneration [28,29]. This grading was made on
hematoxylin-eosin stained sections from all cortical re-
gions. Mild degeneration connotes a superficial shrink-
age and reduction of neurons mainly in cortical layer II,
accompanied by a glial reaction in layers I to III, with or
without a mild laminar microvacuolation. Moderate
degeneration reveals a deeper engagement of cortical
layers, with some reduction of layer V neurons. Severe
degeneration represents a pancortical degeneration with
advanced neuronal loss and a variable but more intense
gliosis accompanied by marked limbic, especially anterior
cingulate and hippocampal, degeneration [28,29]. Further-
more, complementary sectioning and staining for the de-
tection of pathological TAR DNA-binding protein 43
(pTDP-43, Cosmo Bio Ltd., Tokyo, Japan) and the protein
fused in sarcoma (FUS, Sigma-Aldrich LLS, St. Louis,
Table 1 Demographic data for study population
Group N Male/Female Median duration of dementia




LP to death (range)
FTD 34 15/19 3 (1–9) 70 (38–85) -
bvFTD 23 12/11 3 (1–9) 72 (38–85) -
SD 7 2/5 2 (1–4) 64 (53–78) -
PNFA 4 1/3 3 (1–5) 69 (66–77) -
AD 20 7/13 2 (1–7) 72 (49–84) -
Healthy controls 26 12/14 NA 70 (56–83) -
NP verified FTD 10 5/5 3 (0.4-12) 63 (32–78) 2 (0.1-8)
Tau-pos 3 1/2 5 (4–7) 69 (50–78) 3 (2–4)
Tau-neg 7 4/3 3 (0.4-12) 60 (32–67) 2 (0.1-8)
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tin staining were previously available.
Statistics
The NFL values of the clinical group cases were analysed
for each clinical subtype. The NFL values of the
neuropathologically diagnosed FTD cases were analysed
for different protein pathologies and demographic fea-
tures. We used the detection limit (250 ng/L) as the
lowest possible value of NFL in the statistical analyses.
All analyses were carried out in SPSS 19.0. Between-
group differences in CSF biomarkers were analysed
using the non-parametric Kruskal-Wallis test followed
by the Mann–Whitney U test (exact p-value and
corrected for ties). Each group was analysed separately.
A p-value of <0.05 was considered to be statistically
significant. When presenting results for the smallest
groups, the exact p-value is given. The Spearman rank
test was used to check for potential correlations. Because
of the small size of the sample populations, the demo-
graphic data as well as the levels of biomarkers are
presented as medians and range (min – max).
Results
Demographic data
Demographic data for the study population (both patient
groups and the clinical and neuropathological material)
are summarised in Table 1. At the time of LP, the
median age of the AD group was slightly greater than
that of the FTD group, whereas the duration of disease
was somewhat shorter (non-significant differences).
CSF biomarkers in the clinical patient group
The median NFL level for the entire FTD group was sig-
nificantly higher than for both the AD group (p<0.001)
and the healthy controls (p<0.001). NFL levels in both
bvFTD and SD, but not PNFA, were significantly higher
(p<0.001) than in AD (Figure 1 and Table 2). Within theFTD group, the NFL median level was highest in SD,
intermediate in bvFTD and lowest in PNFA, however,
the difference was not statistically significant (asymptotic
p-value 0.068). The following number of NFL samples
were at or below the detection limit in each subgroup:
bvFTD n=1, SD n=0, PNFA n=1, AD n=5, healthy
controls n=17.
Median levels of tau, Aβ42 and phospho-tau (p-tau)
are presented in Table 2. Aβ42 was significantly higher
in the FTD group as a whole compared with the AD
group, while tau and p-tau levels were significantly lower
(p<0.001). The median levels of all three proteins were
similar for bvFTD and SD, while the median levels for
the PNFA group were similar to the AD group values.
These differences were not statistically significant,
probably because of the small group sizes. There was no
correlation between NFL levels and the albumin ratio.CSF biomarkers in the neuropathological patient group
In the patients with neuropathologically verified FTD, al-
though limited in the number of cases, NFL values were
significantly higher in the tau-negative cases (median
1620; range 1050–5546 ng/L) compared with the tau-
positive cases (median 665; range 250–1030 ng/L)
(p=0.017), as shown in Figure 2. There was no correlation
between the assessed severity of cortical degeneration and
levels of NFL.
In these cases, there was no correlation between the
duration of dementia at the time of LP and the levels of
any of the pathological proteins (Table 3). Furthermore,
there was no association between CSF biomarker levels
and neuropathological severity of degeneration, nor be-
tween these markers and brain weight.Discussion
To our knowledge, this study is the largest to date
performed on CSF neurofilament light chain protein
Figure 1 Boxplot with individual values of NFL in each clinical subtype. The number of subjects in each subtype: bvFTD n=23, SD n=7,
PNFA n=4, AD n=20, healthy controls n=26. The detection limit of NFL was 250 ng/l.
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first study on NFL levels in neuropathologically verified
FTD with pathological subtyping. Previous studies have
shown that NFL levels are higher in FTD compared with
both AD and controls [18]. Our results replicate those
findings and extend previous data by reporting NFL
values in different clinical and neuropathological subtypes
of FTD.
The results of the present study need to be interpreted
with caution considering the significant differences in
group size between the diagnostic subtypes. The clinical
diagnosis of patients was established through a rigorous
process to minimise the risk of misdiagnosis. However,
as the clinical diagnosis does not always reflect the
underlying pathology, it is possible that some of the pa-
tients in the clinically diagnosed group did not have
tau-positive or -negative frontotemporal lobar degen-
eration. A strength of this study is that we compared









NFL (ng/L) 844 (250–2760) 770 (250–2760) 1340 (580–1940) 455 (25
Aβ42 (ng/L) 555 (140–1130) 570 (260–1130) 595(360–1110) 215 (14
Tau (ng/L) 355 (150–820) 280 (160–750) 385(180–770) 610 (15









NA Not analysed.with patients who had a neuropathologically verified
diagnosis.
Our clinical data demonstrated that NFL levels were
significantly higher in SD and bvFTD, but not PNFA,
compared with both AD and controls. Within the FTD
group the NFL levels were highest in SD; however, the
differences between subgroups did not reach statistical
significance. This is possibly because of the small number
of cases in the SD and PNFA groups.
NFL values at the detection level (250 ng/L) were
mainly found in the AD and control groups. The possi-
bility that these values could have been even lower is not
thought to have influenced the comparison between
groups as we used non-parametric tests.
The similarities between CSF biomarkers in the small
group of PNFA cases (n=4) and the AD group (n=20)
suggest that there may be individuals with underlying
Alzheimer pathology in the PNFA group, albeit with a






0–1040) 415 (250–860) 250 (250–710) FTD> AD p<0.001 SD>AD
p<0.001 FTDbv> AD p<0.001
0–380) 285 (140–460) NA FTD>AD p<0.001
0–820) 630 (230–2290) NA AD>FTD p<0.001





Figure 2 Scatter of NFL values in each neuropathological subtype. The number of subjects in each subtype: tau-positive n=3, tau-negative
n=7. The detection limit of NFL was 250 ng/l.
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there were significant differences in NFL levels between
subtypes; the tau-negative cases had higher NFL levels
than the tau-positive cases. This fits with our finding in
the clinical data that the SD group had the highest level
of NFL, as this is the clinical presentation most often
associated with TDP-43 pathology [30]. The clinical
presentation of bvFTD can be associated with either a













1 726 819 NA 5546 FTD FTD-TDP43
2 570 410 35 3770 FTD-MND FTD-TDP43
3 420 620 NA 2600 bvFTD FTD-FUS
4 500 450 54 1620 bvFTD FTD-TDP43
5 662 494 NA 1494 bvFTD FTD-FUS
6 411 263 NA 1241 FTD(PPA) FTD-TDP43
7 370 330 29 1050 FTD(PPA) FTD-TDP43
8 780 490 68 1030 bvFTD FTD-tau
9 369 554 95 665 FTD(PPA) FTD-tau
10 639 528 NA <250 AD FTD-tau
PPA Primary progressive aphasia.
NA Not analysed.
NK Not known.keeping with the intermediately increased levels of NFL
in patients with bvFTD in this study compared with the
PNFA and AD groups; the former of which are most
often reported as tau-positive.
Neurofilament protein is a biomarker for neuronal
death and axonal loss. It has previously been shown that
rapidly progressive neurodegenerative disorders such as
PSP and multiple system atrophy have higher mean









moderate 2 54 1020
mild 0.4 62 1600
severe 3 37 NK
severe NK 67 1340
severe 3 34 NK
severe 12 76 975
severe 5 69 760
mild 4 81 1125
severe 7 73 1010
mild NK 53 1335
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moderate to severe regional atrophy on neuroimaging at
the time of CSF sampling is often reflected in elevated
NFL levels. In our neuropathological cases, however,
there was no correlation between NFL levels at the time
of lumbar puncture and the degree of degeneration and
estimated overall severity at the time of death. In
addition, blood–brain barrier dysfunction, measured by
the CSF/serum albumin ratio, did not seem to contribute
to the differences in NFL between subtypes. To establish
whether high NFL levels in CSF reflect aggressive or rapid
neuronal breakdown, longitudinal studies of clinical
progression, neuroimaging and CSF sampling will need to
be performed.
Two out of the 10 neuropathologically verified FTD
cases showed high levels of NFL exceeding 3000 ng/L.
In a previous study, a small fraction of patients within a
larger set of clinically diagnosed patients with FTD had
particularly high NFL levels [32]. Similarly, in a meta-
analysis of CSF NFL levels in dementia, a small number
of FTD patients in each study group had particularly
high levels of CSF NFL and NFH [17]. As these authors
suggested, it is likely that there is an important subgroup
within the FTD spectrum with higher CSF NFL levels.
FTD-MND is exclusively associated with tau-negative
pathology. There is a close relationship between FTD-
MND and ALS, and several studies have shown high
NFL levels in ALS, especially in the most rapidly
progressing cases [19,20].
Conclusions
NFL and other CSF biomarkers may be useful for the dis-
crimination between different forms of FTD disorders, es-
pecially the primary progressive aphasias. Furthermore,
NFL levels may indicate the underlying pathology, with a
high NFL level corresponding to a tau-negative pathology,
most often of the TDP-43 type. Further studies based on a
larger population are needed to confirm our findings.
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